Stryker Call Options Active
Shares in Stryker Corp. (Ticker: SYK) popped 6.0% this week to as high as $85.62 this morning after a report in the Financial Times earlier in the week said the company may be planning to make a bid for orthopaedics company, Smith & Nephew Plc. The company has since said it does not plan to make an offer for Smith & Nephew, but shares remain elevated and at their highest level in roughly a decade. Upside call buying across several expiries on Stryker caught our eye this morning. It looks like some options traders are positioning for shares in the name to continue to push to the upside during the back half of 2014.
Traders appear to have purchased almost 300 of the Jul 90.0 calls at a premium of $0.50 each. These contracts may be profitable at July expiration in the event that SYK shares rally another 6.0% over the current level to exceed the effective breakeven point at $90.50. Meanwhile, the 87.5 strike calls expiring in September and January 2015 were the most traded contracts on Friday morning. It looks like traders shelled out $2.05 in premium to buy more than 800 of the Sep 87.5 strike calls and paid around $3.20 per contract for 1,000 of the Jan ?15 87.5 strike calls. ?
Shares in Stryker are off their highest level of the session, trading up 0.75% at $84.55 as of 11:30 a.m. ET. Shares may have received a lift from a note out of Deutsche Bank about a Stryker bid for Smith & Nephew. Deutsche Bank has a ?Buy? rating on Stryker and a $90.00 price target.
—————————————————————————————-
Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.